Heterogeneity in hormone-dependent breast cancer and therapy: Steroid hormones, HER2, melanoma antigens, and cannabinoid receptors

[1]  Christopher S. Hughes,et al.  Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes , 2022, Nature communications.

[2]  C. Almeida,et al.  Cannabinoids in Breast Cancer: Differential Susceptibility According to Subtype , 2021, Molecules.

[3]  P. Fasching,et al.  Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement , 2021, Cancers.

[4]  S. Mader,et al.  Positive Regulation of Estrogen Receptor Alpha in Breast Tumorigenesis , 2021, Cells.

[5]  S. Salsano,et al.  What Do We Know about Classical and Non-Classical Progesterone Receptors in the Human Female Reproductive Tract? A Review , 2021, International journal of molecular sciences.

[6]  R. Jach,et al.  Steroid Receptors in Breast Cancer: Understanding of Molecular Function as a Basis for Effective Therapy Development , 2021, Cancers.

[7]  E. Rutgers,et al.  Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Young Yang,et al.  Epigenetic Upregulation of MAGE-A Isoforms Promotes Breast Cancer Cell Aggressiveness , 2021, Cancers.

[9]  S. Swain,et al.  HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now , 2021, NPJ breast cancer.

[10]  S. Vacher,et al.  Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant , 2020, Breast cancer research : BCR.

[11]  N. Wilson,et al.  Lobular Breast Cancer: A Review , 2021, Frontiers in Oncology.

[12]  M. Beato,et al.  Signalling Network of Breast Cancer Cells in Response to Progesterone , 2020, bioRxiv.

[13]  V. Villegas,et al.  Resistance and Overcoming Resistance in Breast Cancer , 2020, Breast cancer.

[14]  A. Krivokuca,et al.  The Interplay between Cancer Biology and the Endocannabinoid System—Significance for Cancer Risk, Prognosis and Response to Treatment , 2020, Cancers.

[15]  B. Ramaswamy,et al.  Estrogen Receptor Beta (ERβ): A Ligand Activated Tumor Suppressor , 2020, Frontiers in Oncology.

[16]  K. Fon Tacer,et al.  Emerging roles of the MAGE protein family in stress response pathways , 2020, The Journal of Biological Chemistry.

[17]  R. Subramani,et al.  Classical and Non-Classical Progesterone Signaling in Breast Cancers , 2020, Cancers.

[18]  Noreen Fatima,et al.  Prediction of Breast Cancer, Comparative Review of Machine Learning Techniques, and Their Analysis , 2020, IEEE Access.

[19]  Shondra M. Pruett-Miller,et al.  Translational Repression of G3BP in Cancer and Germ Cells Suppresses Stress Granules and Enhances Stress Tolerance. , 2020, Molecular cell.

[20]  C. Brisken,et al.  Progesterone signalling in the normal breast and its implications for cancer. , 2020, Journal of molecular endocrinology.

[21]  C. Arteaga,et al.  Overcoming Endocrine Resistance in Breast Cancer. , 2020, Cancer cell.

[22]  J. Ostrander,et al.  Steroid Receptors as MAPK Signaling Sensors in Breast Cancer: Let the Fates Decide. , 2020, Journal of molecular endocrinology.

[23]  S. Borstnar,et al.  Cannabinoids and Hormone Receptor-Positive Breast Cancer Treatment , 2020, Cancers.

[24]  Shondra M. Pruett-Miller,et al.  A Cancer-Specific Ubiquitin Ligase Drives mRNA Alternative Polyadenylation by Ubiquitinating the mRNA 3' End Processing Complex. , 2020, Molecular cell.

[25]  Daming Dong,et al.  G Protein-Coupled Estrogen Receptor: A Potential Therapeutic Target in Cancer , 2019, Front. Endocrinol..

[26]  J. Gustafsson,et al.  Nuclear receptors: recent drug discovery for cancer therapies. , 2019, Endocrine reviews.

[27]  Y. Bang,et al.  HER2-targeted therapies — a role beyond breast cancer , 2019, Nature Reviews Clinical Oncology.

[28]  K. Desai,et al.  Pathways to Endocrine Therapy Resistance in Breast Cancer , 2019, Front. Endocrinol..

[29]  Henry W. Long,et al.  Estrogen receptor signaling is reprogrammed during breast tumorigenesis , 2019, Proceedings of the National Academy of Sciences.

[30]  Shondra M. Pruett-Miller,et al.  MAGE cancer-testis antigens protect the mammalian germline under environmental stress , 2019, Science Advances.

[31]  Yun Liu,et al.  Regulation of estrogen signaling and breast cancer proliferation by an ubiquitin ligase TRIM56 , 2019, Oncogenesis.

[32]  T. Thalhammer,et al.  Future Aspects for Cannabinoids in Breast Cancer Therapy , 2019, International journal of molecular sciences.

[33]  M. Behera,et al.  ER+/HER2+ Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER-/HER2+ Breast Cancer. , 2019, Clinical breast cancer.

[34]  Jie Wu,et al.  Cannabis, cannabinoid receptors, and endocannabinoid system: yesterday, today, and tomorrow , 2019, Acta Pharmacologica Sinica.

[35]  P. Silveyra,et al.  Estrogen receptor signaling mechanisms. , 2019, Advances in protein chemistry and structural biology.

[36]  E. Grzybowska,et al.  Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals , 2018, Breast Cancer Research and Treatment.

[37]  M. Sang,et al.  Epigenetic regulation of MAGE family in human cancer progression-DNA methylation, histone modification, and non-coding RNAs , 2018, Clinical Epigenetics.

[38]  J. Carroll,et al.  Signaling pathways and steroid receptors modulating estrogen receptor α function in breast cancer , 2018, Genes & Development.

[39]  C. Ward,et al.  Predictive markers of endocrine response in breast cancer , 2018, World journal of experimental medicine.

[40]  M. Farré,et al.  Cannabinoids: from pot to lab , 2018, International journal of medical sciences.

[41]  L. Whitehead,et al.  Breast surgery for metastatic breast cancer. , 2018, British journal of community nursing.

[42]  C. Vaughan,et al.  Plant-Based Cannabinoids for the Treatment of Chronic Neuropathic Pain , 2018, Medicines.

[43]  Ashton C. Berger,et al.  A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. , 2018, Cancer cell.

[44]  M. Badowski,et al.  Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer , 2018, Therapeutics and clinical risk management.

[45]  C. Mercado,et al.  Ductal Carcinoma In Situ: The Whole Truth. , 2017, AJR. American journal of roentgenology.

[46]  H. Shimizu,et al.  Melanoma antigen A12 regulates cell cycle via tumor suppressor p21 expression , 2017, Oncotarget.

[47]  S. Loibl,et al.  HER2-positive breast cancer , 2017, The Lancet.

[48]  P. Wee,et al.  Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways , 2017, Cancers.

[49]  Anna K. Lee,et al.  A Comprehensive Guide to the MAGE Family of Ubiquitin Ligases. , 2017, Journal of molecular biology.

[50]  M. Nanjan,et al.  Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review. , 2017, Bioorganic chemistry.

[51]  Xin Jin,et al.  MAGE-TRIM28 complex promotes the Warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation , 2017, Oncogenesis.

[52]  E. Wilson,et al.  Melanoma antigen-A11 regulates substrate-specificity of Skp2-mediated protein degradation , 2017, Molecular and Cellular Endocrinology.

[53]  J. Carroll,et al.  Deciphering the divergent roles of progestogens in breast cancer , 2016, Nature Reviews Cancer.

[54]  P. Ferk,et al.  Overlapping molecular pathways between cannabinoid receptors type 1 and 2 and estrogens/androgens on the periphery and their involvement in the pathogenesis of common diseases (Review). , 2016, International journal of molecular medicine.

[55]  P. Jagodziński,et al.  Exploring estrogenic activity in lung cancer , 2016, Molecular Biology Reports.

[56]  E. Levin,et al.  Nuclear receptors outside the nucleus: extranuclear signalling by steroid receptors , 2016, Nature Reviews Molecular Cell Biology.

[57]  Zeynep Madak-Erdogan,et al.  Nuclear and extranuclear-initiated estrogen receptor signaling crosstalk and endocrine resistance in breast cancer , 2016, Steroids.

[58]  Elgene Lim,et al.  Renewed interest in the progesterone receptor in breast cancer , 2016, British Journal of Cancer.

[59]  M. Sang,et al.  The expression of MAGE-C1 and MAGE-C2 in breast cancer and their clinical significance. , 2016, American journal of surgery.

[60]  J. Weon,et al.  The MAGE protein family and cancer. , 2015, Current opinion in cell biology.

[61]  S. Badve,et al.  Tumor Heterogeneity in Breast Cancer , 2015, Advances in anatomic pathology.

[62]  Kevin A. Henry,et al.  Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State , 2015, Journal of the National Cancer Institute.

[63]  M. White,et al.  Degradation of AMPK by a Cancer-Specific Ubiquitin Ligase , 2015, Cell.

[64]  N. Iqbal,et al.  Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications , 2014, Molecular biology international.

[65]  M. Dunning,et al.  Genome-driven integrated classification of breast cancer validated in over 7,500 samples , 2014, Genome Biology.

[66]  Fan Yang,et al.  MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis , 2014, Breast Cancer Research and Treatment.

[67]  V. Speirs,et al.  Identification of MAGEA antigens as causal players in the development of tamoxifen-resistant breast cancer , 2014, Oncogene.

[68]  D. Valmori,et al.  Expression of MAGE-A3/6 in Primary Breast Cancer is Associated With Hormone Receptor Negative Status, High Histologic Grade, and Poor Survival , 2014, Journal of immunotherapy.

[69]  M. Sang,et al.  Expressions of MAGE-A9 and MAGE-A11 in breast cancer and their expression mechanism. , 2014, Archives of medical research.

[70]  C. Perou,et al.  The genomic landscape of breast cancer as a therapeutic roadmap. , 2013, Cancer discovery.

[71]  R. O'Regan,et al.  The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy , 2012, Chemotherapy research and practice.

[72]  S. Young,et al.  Primate-specific Melanoma Antigen-A11 Regulates Isoform-specific Human Progesterone Receptor-B Transactivation* , 2012, The Journal of Biological Chemistry.

[73]  K. Horwitz,et al.  Progesterone receptors, their isoforms and progesterone regulated transcription , 2012, Molecular and Cellular Endocrinology.

[74]  M. Rapé,et al.  The Ubiquitin Code , 2012, Annual review of biochemistry.

[75]  P. Thomas,et al.  Minireview: G protein-coupled estrogen receptor-1, GPER-1: its mechanism of action and role in female reproductive cancer, renal and vascular physiology. , 2012, Endocrinology.

[76]  R. Vadlamudi,et al.  Role of Estrogen Receptor Signaling in Breast Cancer Metastasis , 2011, International journal of breast cancer.

[77]  Carlos L. Arteaga,et al.  Treatment of HER2-positive breast cancer: current status and future perspectives , 2012, Nature Reviews Clinical Oncology.

[78]  A. Simpson,et al.  MAGE I Transcription Factors Regulate KAP1 and KRAB Domain Zinc Finger Transcription Factor Mediated Gene Repression , 2011, PloS one.

[79]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[80]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[81]  A. Simpson,et al.  Multiple Cancer/Testis Antigens Are Preferentially Expressed in Hormone-Receptor Negative and High-Grade Breast Cancers , 2011, PloS one.

[82]  Maojun Yang,et al.  MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. , 2010, Molecular cell.

[83]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  E. Wilson,et al.  Transcriptional Synergy between Melanoma Antigen Gene Protein-A11 (MAGE-11) and p300 in Androgen Receptor Signaling* , 2010, The Journal of Biological Chemistry.

[85]  J. Graham,et al.  Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression , 2009, Nuclear receptor signaling.

[86]  C. Rudlowski,et al.  Male Breast Cancer , 2008, Breast Care.

[87]  Tudor I. Oprea,et al.  Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. , 2008, Annual review of physiology.

[88]  Ian O Ellis,et al.  Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  K. Wagner,et al.  Estrogen receptor-α expression in the mammary epithelium is required for ductal and alveolar morphogenesis in mice , 2007, Proceedings of the National Academy of Sciences.

[90]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[91]  H. Iwase,et al.  [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[92]  G. Coetzee,et al.  Androgen Receptor Signaling , 2004, Cancer Research.

[93]  B. Anderson,et al.  Trends in incidence rates of invasive lobular and ductal breast carcinoma. , 2003, JAMA.

[94]  K. Pantel,et al.  MAGE-A gene expression pattern in primary breast cancer. , 2001, Cancer research.

[95]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[96]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.